Water-soluble fullerene derivatives attenuate exsanguination-induced bronchoconstriction of guinea-pigs.
1. This study investigated the effects of increased antioxidants (administration of water-soluble fullerenol-1 and pre-exposure to chronic hypoxia) as well as an iron-chelating agent (deferoxamine) on exsanguination-induced noncholinergic airway constriction in guinea-pigs. 2. Fullerenol-1 usually did not cause significant alteration in respiratory function (lung volumes, dynamic respiratory compliance, maximal expiratory flow at 50% total lung capacity (Vmax50), and forced expiratory flow at 0.1 s (FEV 0.1) at low (200 micrograms kg-1) or at high doses (2 mg kg-1), except that it produced a slight bronchial constricting action (decreases in both Vmax 50 and FEV 0.1) at high doses (2 mg kg-1) via intratracheal instillation. 3. Beginning 15 min after exsanguination, there was a marked temporal decrease in FEV 0.1, indicating a gradual increase in airway constriction with time. 4. Administration of either fullerenol-1 or deferoxamine, or pre-exposure to chronic hypoxia significantly ameliorated the exsanguination-induced bronchoconstriction. The results provide evidence that oxygen radicals play an important role in exsanguination-induced airway constriction. 5. The significant effects of the increased antioxidants and deferoxamine,however, cannot be explained by the alteration in either tracheal neutral endopeptidase activity or lung tissue substance P level.
Lai
Y L
YL
Department of Physiology, Medical College and Center for Condensed Matter Sciences, National Taiwan University, Taipei, Taiwan.
Chiang
L Y
LY
D000818:Animals; D000931:Antidotes / Q000494:pharmacology*; D016084:Bronchoconstriction / Q000187:drug effects*; D002244:Carbon / Q000494:pharmacology*; D003676:Deferoxamine / Q000494:pharmacology*; D010450:Endopeptidases / Q000378:metabolism; D005105:Expiratory Reserve Volume / Q000187:drug effects; D016166:Free Radical Scavengers / Q000494:pharmacology*; D037741:Fullerenes; D006168:Guinea Pigs; D000860:Hypoxia / Q000503:physiopathology; D008297:Male; D012137:Respiratory System / Q000187:drug effects; D013373:Substance P / Q000378:metabolism
D000931:Antidotes; D016166:Free Radical Scavengers; D037741:Fullerenes; C108127:fullerenol; D013373:Substance P; D002244:Carbon; D010450:Endopeptidases; D003676:Deferoxamine